Generic Lokelma Availability
Last updated on Apr 10, 2025.
Lokelma is a brand name of sodium zirconium cyclosilicate, approved by the FDA in the following formulation(s):
LOKELMA (sodium zirconium cyclosilicate - for suspension;oral)
-
Manufacturer: ASTRAZENECA
Approval date: May 18, 2018
Strength(s): 5GM/PACKET [RLD], 10GM/PACKET [RLD]
Is there a generic version of Lokelma available?
No. There is currently no therapeutically equivalent version of Lokelma available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lokelma. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Extended use zirconium silicate compositions and methods of use thereof
Patent 10,300,087
Issued: May 28, 2019
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.
Patent expiration dates:
- October 14, 2035✓✓
- October 14, 2035
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 10,335,432
Issued: July 2, 2019
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F. & Gilmore Jeff
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 10,398,730
Issued: September 3, 2019
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 10,413,569
Issued: September 17, 2019
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 10,695,365
Issued: June 30, 2020
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- October 22, 2033✓
- October 22, 2033
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 11,406,662
Issued: August 9, 2022
Inventor(s): Keyser; Donald Jeffrey et al.
Assignee(s): ZS PHARMA, INC. (Coppell, TX)The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Extended use zirconium silicate compositions and methods of use thereof
Patent 11,738,044
Issued: August 29, 2023
Inventor(s): Keyser; Donald Jeffrey et al.
Assignee(s): ZS PHARMA, INC. (Coppell, TX)The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.
Patent expiration dates:
- October 14, 2035✓
- October 14, 2035
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 8,802,152
Issued: August 12, 2014
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS Pharma, Inc.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- April 19, 2032✓
- April 19, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 8,808,750
Issued: August 19, 2014
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS Pharma, Inc.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 8,877,255
Issued: November 4, 2014
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS Pharma, Inc.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- October 22, 2033✓
- October 22, 2033
-
Extended use zirconium silicate compositions and methods of use thereof
Patent 9,592,253
Issued: March 14, 2017
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.
Patent expiration dates:
- October 14, 2035✓✓
- October 14, 2035
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 9,844,567
Issued: December 19, 2017
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 9,861,658
Issued: January 9, 2018
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- February 10, 2032✓
- February 10, 2032
-
Microporous zirconium silicate for the treatment of hyperkalemia
Patent 9,913,860
Issued: March 13, 2018
Inventor(s): Keyser Donald Jeffrey & Guillem Alvaro F.
Assignee(s): ZS PHARMA, INC.The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of ZS-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.
Patent expiration dates:
- October 22, 2033✓✓
- October 22, 2033
More about Lokelma (sodium zirconium cyclosilicate)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (3)
- Drug images
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: cation exchange resins
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
Term | Definition |
---|---|
Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.